CAR‐T cell therapy for non‐Hodgkin lymphomas: A new treatment paradigm

Hill, LaQuisa; Lulla, Premal; Heslop, Helen E.

doi:10.1002/acg2.54

Cited by 9 publications

(8 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another complication is immune effector cell associated neurotoxicity syndrome (ICANS). ICANS can occur with or without CRS, and patients usually present in the first 2 weeks post‐CAR T‐cell therapy with symptoms related to the nervous system including encephalopathy, aphasia, ataxia, and seizures 69 . Although rarely, patients may manifest fatal cerebral edema or hemorrhage.…”

Section: Novel Treatments For Nhl and Their Potential Complicationsmentioning

confidence: 99%

The forgotten survivor: A comprehensive review on Non‐Hodgkin lymphoma survivorship

et al. 2022

View full text Add to dashboard Cite

The number of non-Hodgkin lymphoma (NHL) survivors is increasing. With the advancement of NHL therapies, it is crucial to focus on the challenges these survivors may face. Three main categories are to be considered in NHL survivorship, including quality of life and uncertainty about the future, possible physical health complications (including cardiovascular disease, infertility, and subsequent neoplasms), and the impact of novel NHL treatments and their potential complications. The latter includes CAR T-cell therapy, monoclonal antibodies, checkpoint inhibitors, and hematopoietic stem cell transplantation. In this report, we aim to shed the light on these aspects and to discuss survivorship care plan for NHL. | INTRODUCTIONIn the United States (US), more than 80 000 patients are diagnosed with non-Hodgkin lymphoma (NHL) annually, 1 and are considered survivors. 2 NHL comprises 4% of all malignancies; however, its impact on survivorship is disproportionate to its incidence due to the higher rates of survival compared with many more common cancers. The American Cancer Society (ACS) predicts that the incidence will rise as people in the U.S. continue to live longer and the risk of NHL increases with age. 1,3 Although this number is expected to proportionally grow with time as more patients are diagnosed and survive with NHL, cancer survivorship care in NHL survivors remains understudied (Figure 1).Cancer survivorship has become an essential part of the cancer care spectrum since formally described in 1986. 4 Many societies and committees are now available to help and guide survivors, their families, and physicians. For instance, the ACS currently has survivorship care guidelines for various solid tumors, including breast, prostate, colorectal, and head and neck cancers. 5 In the field of lymphoma, professional societies are actively developing such guidelines; however, a discrepancy in survivorship care between HL and NHL is observed, favoring HL, despite NHL being more prevalent. This is likely due to From the time of diagnosis onward, NHL patients face several challenges that can impact their physical, mental, and psychosocial wellbeing. 6 A population-based study 7 on 360 NHL patients 5-15 year after diagnosis (82% response rate) assessed their Health-Related Quality of Life (HRQoL) using the 36-item Short-Form Health Survey

show abstract

Section: Novel Treatments For Nhl and Their Potential Complicationsmentioning

confidence: 99%

The forgotten survivor: A comprehensive review on Non‐Hodgkin lymphoma survivorship

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Thus far, adverse effects have been tolerable, with no patients having cytokine release syndrome greater than grade 3 in severity [ 180 ]. CAR T-cell therapy is thus a potential treatment modality for patients with R/R NHL on the basis of its promising preliminary results in pediatric patients and its positive outcomes in adult patients with NHL [ 181 ].…”

Section: Advances In the Treatment Of Pediatric And Adolescent Nhlmentioning

confidence: 99%

Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective

Sheikh

Elgehiny²,

Ragoonanan

et al. 2022

Cancers

View full text Add to dashboard Cite

Non-Hodgkin lymphoma (NHL) is a broad entity which comprises a number of different types of lymphomatous malignancies. In the pediatric and adolescent population, the type and prognosis of NHL varies by age and gender. In comparison to adults, pediatric and adolescent patients generally have better outcomes following treatment for primary NHL. However, relapsed/refractory (R/R) disease is associated with poorer outcomes in many types of NHL such as diffuse large B cell lymphoma and Burkitt lymphoma. Newer therapies have been approved in the use of primary NHL in the pediatric and adolescent population such as Rituximab and other therapies such as chimeric antigen receptor T-cell (CAR T-cell) therapy are under investigation for the treatment of R/R NHL. In this review, we feature the characteristics, diagnosis, and treatments of the most common NHLs in the pediatric and adolescent population and also highlight the differences that exist between pediatric and adult disease. We then detail the areas of treatment advances such as immunotherapy with CAR T-cells, brentuximab vedotin, and blinatumomab as well as cell cycle inhibitors and describe areas where further research is needed. The aim of this review is to juxtapose established research regarding pediatric and adolescent NHL with recent advancements as well as highlight treatment gaps where more investigation is needed.

show abstract

“…Although not commonly considered treatable, indolent B cell NHLs, such as follicular lymphoma (FL), can be treated for many years with a favorable prognosis. A proportion of indolent B cell NHLs, on the other hand, can undergo histologic transition into more aggressive B cell NHLs (Hill et al, 2019).…”

Section: Diagnosis and Treatment Of Nhlmentioning

confidence: 99%

Review: Myeloid-derived suppressor cells (MDSCs) – Will it become a therapeutic target for NonHodgkin Lymphoma?

Kottahachchi¹,

Gallage²,

Nandasena³

2021

IJRIAS

View full text Add to dashboard Cite

Non-Hodgkin's lymphoma (NHL) is a varied set of lymphoproliferative disorders initiatingfrom B, T, or natural killer (NK) lymphocytes. Common treatments of NHL include chemotherapy regimens, radiotherapy, rituximab administration, transfusion of blood products and Peripheral blood stem cell transplantation. Recently, several targeted therapies have been approved or are in the later phase of clinical trials and molecular targeted therapy is considered as a key aspect of NHL. Successful treatment of lymphoma may result from the induction of specific antitumor immunity. Myeloid-derived suppressor cells (MDSC) are being investigated as a possible target in solid tumors and most of blood cancers to improve the effects of commonly used undergoing treatment. The anti-tumor immune response of a diseased person is inhibited by MDSC expansion, which restricts, cytokine secretion, T cell proliferation and the activation of regulatory T cells. In order to identify immunological therapeutic targets, it is critical to identify tumor-promoting factors. Since this environment is focus to low selective pressure for mutations, targeting the Tumor Microenvironment (TME) is a promising therapeutic option for Non-Hodgkin lymphoma. The features, distribution, roles, cellular reactions, and aiming MDSCs in Non-Hodgkin lymphoma are discussed in this review.

show abstract

CAR‐T cell therapy for non‐Hodgkin lymphomas: A new treatment paradigm

Cited by 9 publications

References 81 publications

The forgotten survivor: A comprehensive review on Non‐Hodgkin lymphoma survivorship

The forgotten survivor: A comprehensive review on Non‐Hodgkin lymphoma survivorship

Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective

Review: Myeloid-derived suppressor cells (MDSCs) – Will it become a therapeutic target for NonHodgkin Lymphoma?

Contact Info

Product

Resources

About